Urology Times

09/22/2026

Hackensack University Medical Center's urology program is ranked in the top 5% in the country by U.S. News & World Report. In addition, Hackensack University Medical Center is the only #1 Adult and Children’s Hospital in NJ.

Learn more about the nationally ranked program and the quality care offered to the community: https://www.hackensackmeridianhealth.org/en/services/urology

09/16/2026

The FDA has granted clearance to the LigaSure RAS Maryland jaw device for use with Medtronic’s Hugo robotic-assisted surgery system.

The clearance expands access to the LigaSure vessel-sealing technology within robotic surgical workflows.

09/11/2026

Today, we remember September 11, 2001, and the nearly 3,000 lives lost. We honor the first responders who ran toward danger, the families who lost loved ones, and the communities forever changed by that day.

09/11/2026

ONLINE WEBINAR | The Evolving Role of Testosterone Therapy in Men’s Health

How is emerging evidence changing the conversation around testosterone therapy and prostate health?

Join Urology Times for an expert discussion with Amy Pearlman, MD; Abraham Morgentaler MD, FACS; and Mohit Khera, MD, MBA, MPH on October 1 from 8–9 PM ET.

The panel will discuss:
• Evolving FDA/HHS recommendations for testosterone therapy
• The clinical impact of testosterone deficiency
• Testosterone therapy and prostate safety
• New perspectives on testosterone and prostate cancer
• Practical considerations for men with testosterone deficiency, prostate cancer, and BPH

🔗Register today and join us online: https://hubs.li/Q04x9dfW0

09/07/2026

Labor Day is a time to celebrate the contributions, achievements, and dedication of American workers.

Today, we recognize the urologists, researchers, and health care professionals whose work continues to advance urologic care and make a difference for patients.

Wishing you a safe and happy Labor Day from Urology Times!

08/19/2026

The FDA has granted Breakthrough Therapy and Fast Track designations to 68Ga-NYM096, an investigational CAIX-targeted radiopharmaceutical imaging agent for PET imaging of clear cell renal cell carcinoma.

The designations were based on preliminary clinical data with 68Ga-NYM096, including a small, multicenter study presented at ASCO 2026.

08/18/2026

Is AI really necessary for physicians—or is it simply another tool adding to an already demanding workload?

Giovanni Cacciamani, MD, FEBU, explains why physicians don’t need AI for everything, but why the right AI solutions could fundamentally change how they practice medicine.

As he puts it: physicians who embrace AI may ultimately have an advantage over those who don’t.

Watch his perspective on AI’s evolving role in urology and the future of clinical practice and read the full article: https://hubs.li/Q04tqFgf0

08/17/2026

UroGen Pharma has submitted a new drug application to the FDA seeking approval of UGN-103 (mitomycin) for intravesical solution for recurrent low-grade intermediate-risk non–muscle invasive bladder cancer.

The NDA submission is supported by data from the phase 3 UTOPIA trial.

08/13/2026

Data from the phase 3 LITESPARK-011 trial have been published in The Lancet, showing a significant improvement in progression-free survival with belzutifan plus lenvatinib vs cabozantinib in patients with previously treated advanced clear cell renal cell carcinoma.

Belzutifan plus lenvatinib significantly improved progression-free survival vs cabozantinib in patients with previously treated advanced clear cell renal cell carcinoma.

08/13/2026

Great medical education starts with great partnerships.

We’re grateful to work alongside physicians and experts who bring their expertise to the conversations that matter most in urology.

Dr. Herb Lepor of NYU Langone Health recently joined Urology Times in the studio, and we’re proud to share his perspective on his experience working with all of us at MJH Life Sciences®.

We look forward to continuing to create meaningful opportunities for experts to share their voices with the urology community.